Targovax to present and attend at upcoming conferences

Oslo, 7 December 2022 – Targovax ASA announces that members of its executive management team are invited to present at following upcoming conferences:

7th Annual Oncolytic Virotherapy Summit, Boston, USA
Date: 7 December 2022
Presenter: Erik Digman Wiklund, CEO
Time: 12:00 EDT / 18:00 CET

DNB Nordic Healthcare Conference, Oslo, Norway
Date: 15 December 2022
Presenter: Erik Digman Wiklund, CEO
Time: 15:10 CET

Biotech Showcase, J.P. Morgan Healthcare week
Date: 9-12 January 2023
Attending: Erik Digman Wiklund, CEO, Lubor Gaal, CFO


For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax’s focus is to activate the patient’s immune system to fight cancer, and to bring benefit to cancer patients with few available treatment alternatives. Targovax is developing its product candidates in different cancer indications, including melanoma, mesothelioma, and multiple myeloma, and has demonstrated a favorable safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system against the tumor. Following very encouraging clinical data in several indications, both as monotherapy and in combinations, ONCOS-102 is progressing into a randomized phase 2 trial in melanoma patients resistant to PD-1 checkpoint inhibitor treatment.

Building on successful clinical studies which have provided deep mechanistic insights into the tumor biology and the human immune systems, Targovax is researching circular RNA (circRNA) as novel cancer medicines. In addition, Targovax has a KRAS immunotherapy program, with lead cancer vaccine candidate, TG01, expected to enter the clinic in an enhanced format in the second half of 2022.  Together this provides Targovax with a rich pipeline of innovative future immunotherapy product candidates to follow ONCOS-102.